Close Menu

NEW YORK (GenomeWeb) – Liquid biopsy test developer OncoCyte announced today its public offering of about 9.3 million shares of its common stock at $3.75 per share for gross proceeds of approximately $35 million.

The company has also granted the underwriters a 30-day option to purchase up to an additional 1.4 million shares of common stock at the public offering price to cover any overallotments.

Piper Jaffray is acting as the sole book-running manager and Janney Montgomery Scott is acting as the comanager for the offering, which should close on or about February 12.   

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.